WO2023120583A1 - Composition externe pour l'acné, et composition externe pour effet antimicrobien/stérilisant sélectif d'une bactérie de l'acné - Google Patents

Composition externe pour l'acné, et composition externe pour effet antimicrobien/stérilisant sélectif d'une bactérie de l'acné Download PDF

Info

Publication number
WO2023120583A1
WO2023120583A1 PCT/JP2022/047132 JP2022047132W WO2023120583A1 WO 2023120583 A1 WO2023120583 A1 WO 2023120583A1 JP 2022047132 W JP2022047132 W JP 2022047132W WO 2023120583 A1 WO2023120583 A1 WO 2023120583A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibacterial
fatty acid
component
acid esters
composition
Prior art date
Application number
PCT/JP2022/047132
Other languages
English (en)
Japanese (ja)
Inventor
奈保 栗原
Original Assignee
ライオン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社 filed Critical ライオン株式会社
Publication of WO2023120583A1 publication Critical patent/WO2023120583A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention (I) Acne topical composition and acnes-selective antibacterial/bactericidal composition containing isopropylmethylphenol;
  • the present invention relates to an antibacterial/bactericidal agent for P. acnes and an antibacterial/bactericidal composition for external use on the skin containing the same.
  • IPMP Isopropyl methylphenol
  • IPMP is widely used as a bactericidal agent for acne medicines, but because of its broad antibacterial spectrum, it has the problem of sterilizing not only P. acnes but also Staphylococcus epidermidis, which is useful for moisturizing the skin.
  • Staphylococcus epidermidis is present as a beneficial indigenous skin bacterium. It is known that an increase in Staphylococcus aureus, which is a resident skin bacterium, exacerbates the symptoms. In addition, the acne bacillus Cutibacterium acnes proliferates in sebum and develops acne vulgaris due to an imbalance of the skin flora. For this reason, external medicines have conventionally contained bactericides such as benzalkonium chloride in order to sterilize and remove these harmful Staphylococcus aureus and Acne bacilli (Patent Document: Japanese Patent Application Laid-Open No. 2000-319171).
  • staphylococcus epidermidis which is a beneficial bacterium involved in skin barrier function and skin moisturizing effect, is also sterilized. In some cases, a therapeutic effect (skin moisturizing action) could not be obtained.
  • the present invention has been made in view of the above circumstances, and is a composition containing isopropylmethylphenol, which has excellent antibacterial and bactericidal effects against P. acnes and has an effect on the growth of Staphylococcus epidermidis.
  • the purpose of the present invention is to provide a composition for external use for acne and a composition for external use for acne bacteria-selective antibacterial and sterilization.
  • an antibacterial/bactericidal agent that has excellent antibacterial/bactericidal effects against P. acnes, in particular, has excellent antibacterial/bactericidal effects against P. acnes and does not inhibit the growth of Staphylococcus epidermidis.
  • the purpose of the present invention is to provide an agent (selective antibacterial/bactericidal agent) and an antibacterial/bactericidal composition for external use on the skin containing the same.
  • composition containing (A) isopropylmethylphenol contains (B) pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenate.
  • yl ethyl ether, and (C1) polyethylene glycol fatty acid esters and polyoxyethylene sorbitol fatty acid esters having an HLB of less than 15.0 and a fatty acid chain length of 12 to 18, and polyoxyethylene having an alkyl chain length of 12 to 18
  • the external composition for acne has excellent antibacterial and bactericidal effects against P.
  • acnes preferably Staphylococcus aureus
  • the inventors have found that an antibacterial/bactericidal composition for external use selective for P. acnes can be obtained, and have completed the present invention.
  • a component selected from pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether has an antibacterial and bactericidal action against P. acnes, especially an excellent antibacterial and bactericidal effect against P. acnes.
  • the inventors have found that they have the following properties and that they do not inhibit the growth of Staphylococcus epidermidis, leading to the completion of the present invention.
  • An external composition for acne comprising (A) isopropylmethylphenol and one or more components selected from the following components (B) and (C1). (B) one or more selected from pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether (C1) polyethylene glycol having an HLB of less than 15.0 and a fatty acid chain length of 12 to 18 One or more selected from fatty acid esters, polyoxyethylene sorbitol fatty acid esters, sorbitan fatty acid esters, polyglycerin fatty acid esters, and polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18 [I-2] The topical composition for acne according to I-1, wherein the content of component (A) is 0.01 to 0.3% by mass.
  • composition for external use for acne according to I-1 or I-2 wherein the total content mass ratio of the component (B) and the component (C1) to the content of the component (A) is 1-350.
  • the external composition for acne according to any one of I-1 to I-3 comprising the component (A), the component (B), and the component (C1).
  • (A) isopropylmethylphenol and one or more components selected from the following components (B) and (C1): acnes-selective antibacterial/sterilizing composition for external use.
  • pantothenic acid calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether
  • C1 polyethylene glycol having an HLB of less than 15.0 and a fatty acid chain length of 12 to 18
  • fatty acid esters polyoxyethylene sorbitol fatty acid esters, sorbitan fatty acid esters, polyglycerin fatty acid esters, and polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18
  • the antibacterial/bactericidal agent according to II-1 containing one or more selected from polyoxyethylene alkyl ethers.
  • the antibacterial/disinfectant according to II-1 or II-2 which is a selective antibacterial/disinfectant.
  • an external composition for acne a selective antibacterial/bactericidal external application for acne bacteria, which has excellent antibacterial and bactericidal effects against acne bacteria and has a low influence on the growth of Staphylococcus epidermidis
  • a composition can be provided.
  • an antibacterial/bactericidal agent having excellent antibacterial/bactericidal effects against P. acnes, particularly having excellent antibacterial/bactericidal effects against P. acnes and inhibiting the growth of Staphylococcus epidermidis It is possible to provide an antibacterial/bactericidal agent (selective antibacterial/bactericidal agent) against P. acnes, and an antibacterial/bactericidal external composition for skin containing the same.
  • FIG. 2 is a binary minimum inhibitory concentration diagram of panthenol, polyethylene glycol monolaurate (10EO), and a mixture of panthenol and polyethylene glycol monolaurate (10EO) against Acne bacilli.
  • FIG. 2 is a binary minimum inhibitory concentration diagram of panthenol, polyethylene glycol monolaurate (10EO), and a mixture of panthenol and polyethylene glycol monolaurate (10EO) against Staphylococcus aureus.
  • FIG. 2 is a binary minimum inhibitory concentration diagram of panthenol, polyethylene glycol monolaurate (10EO), and a mixture of panthenol and polyethylene glycol monolaurate (10EO) against S. epidermidis.
  • Embodiment (I) of the present invention is a topical composition for acne containing (A) isopropylmethylphenol and one or more components selected from the following components (B) and (C1). .
  • (B) one or more selected from pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether (C1) polyethylene glycol having an HLB of less than 15.0 and a fatty acid chain length of 12 to 18
  • composition for external use for acne " P. acnes-selective antibacterial/sterilizing composition for external use” is collectively referred to as “composition”.
  • the (A) component of the present invention is (A) isopropylmethylphenol.
  • IPMP is a bactericidal agent that is effective against diseases such as eczema, dermatitis, and acne that are likely to be aggravated by bacteria and fungi. Therefore, it is effective for acne treatment and prevention.
  • the content of component (A) is preferably 0.01 to 0.3% by mass, more preferably 0.03 to 0.3% by mass, relative to the composition in the embodiment (I) of the present invention, 0.05 to 0.3% by mass is more preferable.
  • the amount is 0.01% by mass or more, the bactericidal/antibacterial effect against P. acnes is easily obtained, and when the amount is 0.3% by mass or less, the growth of Staphylococcus epidermidis is less likely to be inhibited.
  • Isopropylmethylphenol has lower bactericidal activity per unit concentration than quaternary ammonium salt-type bactericides such as benzalkonium chloride, is oil-soluble, and has extremely low solubility in water.
  • the component (B) of the present invention is one or more selected from pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether, and can be used singly or in combination of two or more. .
  • Component (B) has excellent antibacterial and bactericidal effects against P. acnes, and has little effect on the growth of Staphylococcus epidermidis.
  • the component (A) alone does not exhibit a bactericidal/antibacterial effect against P. acnes
  • the content of the component (A) does not show a bactericidal/antibacterial effect.
  • panthenol and pantothenyl ethyl ether are preferable as the component (B).
  • Panthenol which is a water-soluble vitamin, is known to have anti-inflammatory action, activation of skin cells, enhancement of skin elasticity and water retention, and the like.
  • Panthenol and salts of pantothenic acid such as calcium pantothenate and sodium pantothenate are converted to pantothenic acid inside the skin and exhibit the above pharmacological effects.
  • Pantothenyl ethyl ether is the ethyl ether of panthenol, which like panthenol is converted to pantothenic acid in the body.
  • component (B) is preferably 0.1 to 2% by mass with respect to the composition in the embodiment (I) of the present invention, and 0.1 to 1 % by mass is more preferred, and 0.3 to 1% by mass is even more preferred.
  • 0.1% by mass or more the bactericidal and antibacterial effects against acne bacteria are improved.
  • the influence on growth of Staphylococcus epidermidis becomes low by making it 0.1 mass % or more and 2 mass % or less.
  • Component (C1) which is the embodiment (I) of the present invention, has an HLB of less than 15.0 and a fatty acid chain length of 12 to 18.
  • Polyethylene glycol fatty acid ester, polyoxyethylene sorbitol fatty acid ester, sorbitan fatty acid It is one or more selected from esters, polyglycerin fatty acid esters, and polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18, and can be used singly or in combination of two or more.
  • the fatty acid chain length or alkyl chain length of component (C1) is 12 to 18, with 12, 14 and 18 being preferred. By setting it as such fatty acid chain length or alkyl chain length, an antibacterial / bactericidal effect improves.
  • the component (A) alone does not exhibit a bactericidal / antibacterial effect, and the component (C1) is added to prevent acne. Antibacterial and bactericidal effects can be obtained selectively against bacteria.
  • (A) component alone exhibits a bactericidal and antibacterial effect against Staphylococcus epidermidis, and in the content of (A) component, by also containing (C1) component, the effect on the growth of Staphylococcus epidermidis can be lowered.
  • the number of added moles of polyoxyethylene is preferably 6 to 60, more preferably 6 to 55, even more preferably 6 to 40, particularly preferably 6 to 25, and most preferably 10.
  • the HLB of component (C1) is less than 15.0, preferably 10.0 to 13.0. Within the above range, it becomes easier to interact with the cell walls and cell membranes of bacteria, so that excellent antibacterial and bactericidal effects against P. acnes and Staphylococcus aureus are likely to be obtained.
  • HLB Hydrophile Balance
  • HLB Hydrophile Balance
  • HLB can be calculated by any one of the Atlas method, Griffin method, Davis method, Kawakami method, etc., and the value published by the manufacturer of the product can be taken into consideration.
  • HLB in the present specification is "Handbook-Cosmetics/Drug Ingredients-Revised Edition", published by Nikko Chemicals Co., Ltd., February 1, 1977, revised edition, pp. 854-855. It is calculated based on As a specific method for determining the HLB value, the component (C1) is combined with sorbitan monostearate (NIKKOL SS-10, HLB 4.7) as a standard emulsifier, and the total amount of these two emulsifiers is Emulsify the liquid paraffin (HLB 10.1), which is the material to be emulsified, by keeping the ratio constant and changing only the ratio, and after leaving it for a day and night, the optimum emulsifier where stability is obtained from the amount of creaming, cloudiness, water separation of the lower layer, etc.
  • HLB 10.1 liquid paraffin
  • HLB value x of the component (C1) is calculated by the following formula (1).
  • y (x x amount used (% by mass) + z x amount used (% by mass))/100
  • x indicates the HLB value of the component (C1)
  • y indicates the HLB value of liquid paraffin
  • z indicates sorbitan monostearate (NIKKOL SS-10) shows the HLB value.
  • the HLB value of the liquid paraffin was determined by the same method using a combination of sorbitan monostearate (NIKKOL SS-10, HLB 4.7) and POE sorbitan monostearate (NIKKOL TS-10, HLB 14.9). can ask.
  • polyethylene glycol fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyethylene glycol monooleate (10EO), polyethylene glycol monooleate (6EO), polyethylene glycol monolaurate (10EO), and polyethylene glycol monostearate (10EO). are mentioned. Numerical values in parentheses in the description of the polyethylene glycol fatty acid esters exemplified above represent the average degree of polymerization of ethylene oxide, that is, the average number of repeating oxyethylene groups. The same applies to the following polyoxyethylene sorbite fatty acid esters and polyoxyethylene alkyl ethers.
  • polyoxyethylene sorbitol fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyoxyethylene sorbitol tetrastearate (60EO), polyoxyethylene sorbitol tetraoleate (60EO), polyoxyethylene sorbitol tetraoleate (40EO), polyoxyethylene sorbitol tetraoleate (30EO) and the like.
  • the fatty acid chain length is preferably 12-18, more preferably 12.
  • Monoesters are also preferred. Specific examples include sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, sorbitan sesquioleate and the like.
  • Polyglycerin fatty acid esters with a fatty acid chain length of 12 to 18 include polyglycerin fatty acid esters such as decaglyceryl monomyristate, polyglyceryl-10 monostearate, and polyglyceryl-10 monooleate.
  • the numerical value at the end of the notation of the polyglycerin fatty acid ester exemplified above represents the average degree of polymerization of glycerin.
  • polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18 examples include polyoxyethylene (4) lauryl ether, polyoxyethylene (9) lauromacrogol such as lauryl ether; polyoxyethylene (10) cetyl ether, polyoxyethylene Ethylene (10) oleyl ether and the like can be mentioned.
  • the (C1) component is preferably a polyethylene glycol (4-20 EO) fatty acid ester having a fatty acid chain length of 12-18, preferably a monoester, from the standpoint of sustained moistness (moisturizing feeling).
  • the content of the component (C1) is preferably 0.1% by mass or more in the composition in the embodiment (I) of the present invention from the viewpoint of having more antibacterial and bactericidal effects, and the effect on the growth of Staphylococcus epidermidis is preferably 10% by mass or less, more preferably 0.1 to 8% by mass, even more preferably 0.3 to 6% by mass, and particularly preferably 1 to 3% by mass.
  • the antibacterial / bactericidal effect with respect to P. acnes and Staphylococcus aureus improves more.
  • the influence on the growth of Staphylococcus epidermidis becomes lower.
  • the influence of the growth of Staphylococcus epidermidis is reduced by containing the component (A) and one or more selected from the components (B) and (C1). Antibacterial and bactericidal effects against acne bacteria can be obtained. It is preferable to contain the component (A), the component (B), and the component (C1) in order to obtain this effect with a small content of the component (A). By containing components (A) to (C1), excellent antibacterial and bactericidal effects against Staphylococcus aureus can be obtained in addition to P. acnes.
  • the total content mass ratio of the component (B) and the component (C1) to the content of the component (A) ((B) + (C1)) / (A)) is preferably 1 to 350, more preferably 3 to 200, and more preferably 8 to 150.
  • the antibacterial / bactericidal effect with respect to P. acnes and Staphylococcus aureus is improved more, and it can exhibit the antibacterial / bactericidal effect aimed at with little content of (A) component.
  • the influence on the growth of Staphylococcus epidermidis becomes lower.
  • the upper limit of the content mass ratio of component (B) to the content of component (A) is preferably 150 or less. , 100 or less, and even more preferably 50 or less.
  • the lower limit of the (B)/(A) mass ratio may be 0, more preferably 1 or more, and even more preferably 3 or more.
  • the lower and upper limits of the (B)/(A) mass ratio are more preferably 1-100, and even more preferably 3-50.
  • the upper limit of the content mass ratio of the component (C1) to the content of the component (A) is preferably 250 or less. , is more preferably 200 or less, and even more preferably 100 or less.
  • the lower limit of the (C1)/(A) mass ratio may be 0, more preferably 2 or more, and even more preferably 5 or more.
  • the lower and upper limits of the (C1)/(A) mass ratio are more preferably 2 to 200, and even more preferably 5 to 100.
  • the composition of the present invention does not deteriorate the feeling of use (stickiness, etc.) when applied to the skin, and the effect on the growth of Staphylococcus epidermidis is reduced.
  • composition for external use for acne composition for external use for acne bacteria-selective antibacterial and sterilization
  • the composition in embodiment (I) of the present invention is applied in an appropriate amount (depending on the application area, but generally 0.1 to 0.5 g [solid or semi-solid such as cream, gel, etc.)].
  • Form formulation 1 to 5 mL [liquid formulation such as lotion, aerosol]) is applied to the skin, at least acne bacteria are antibacterial and sterilized, and the effect on the growth of Staphylococcus epidermidis, which is a resident skin bacterium. is low.
  • the composition for external use may contain the component (A) and one or more selected from the components (B) and (C1). ) component, (B) component, and (C1) component.
  • the composition of the present invention is suitable as an external composition for acne, prevention of acne, treatment of acne, amelioration of acne, and skin moisturizing.
  • it is suitable as an external composition for acne bacteria selective antibacterial / sterilization that has antibacterial / sterilizing against P.
  • acnes and less influence on the growth of Staphylococcus epidermidis and is antibacterial against P. acnes and Staphylococcus aureus.
  • the judgment criteria for "antibacterial/sterilization” and “low effect on growth” are based on the examples described later.
  • the composition in the embodiment (I) of the present invention in particular, in the composition for external use for acne bacteria-selective antibacterial and sterilization, from the viewpoint that the effect on the growth of Staphylococcus epidermidis is low, sterilization in the external preparation
  • the ingredients hydrogen peroxide, sodium hypochlorite, isopropanol, ovanol, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, cresol, popillon iodine, iodine, sodium dichloroisocyanurate, chlorhexidine and acrinol are substantially (effective concentration). Not containing substantially means less than 0.3% by mass, more preferably less than 0.1% by mass, more preferably less than 0.01% by mass, and does not contain (below the detection limit) of the composition. Especially preferred.
  • the dosage form and properties of the composition in the embodiment (I) of the present invention are not particularly limited as long as they can be applied transdermally, and are liquid, solid, semi-solid (gel, ointment, paste, foam). and so on.
  • the embodiment may be in any form such as an external skin drug, an external skin quasi-drug, a cosmetic, a skin cleanser (such as a facial cleanser), and the like.
  • the formulation form of the composition is not particularly limited, and examples include ointments, creams, lotions, gels, emulsions, liquids, patches, mists, foamy sprays, mists, and powders.
  • foamy or paste-like aerosol agents pack agents, body shampoos, hair shampoos, rinses, and the like.
  • ointments, creams, lotions, gels, aerosols, sprays, emulsions, and packs are preferable, and creams, lotions, emulsions, foamy aerosols, and foamy jets. Pump sprays are more preferred.
  • the emulsified state of creams, milky lotions, etc. is not particularly limited, and may be any of W/O, O/W, W/O/W, and O/W/O.
  • a moisturizing effect can be obtained from the selective antibacterial and bactericidal effects, and a moisturizing effect can also be obtained.
  • the reason for this is that it has little effect on the growth of Staphylococcus epidermidis, which is a resident skin bacterium. Staphylococcus epidermidis breaks down sweat and sebum to produce fatty acids and glycerin. Fatty acids keep the skin slightly acidic and produce antibacterial peptides, which can prevent the growth of Staphylococcus aureus.
  • the produced glycerin is a moisturizing ingredient that gives moisture to the skin and plays a role in maintaining the skin barrier function, so that a moisturizing effect can be obtained and a moisturizing feeling can be obtained.
  • post-pubertal acne so-called adult acne
  • the moisturizing function of the stratum corneum is reduced, making it easier to dry.
  • the keratin becomes hard and clogged pores are likely to occur, creating an environment in which anaerobic P. acnes can easily proliferate (inflammation is induced and acne occurs). Therefore, it is important to prevent the skin from drying out.
  • the antibacterial/bactericidal agent of the present invention is suitable as an acne-reducing agent, a skin moisturizing agent, or an agent having both effects.
  • the pH of the composition in the embodiment (I) of the present invention is preferably 3 or higher, preferably 3.0 or higher, and more preferably 3.5 or higher, from the viewpoint of antibacterial/bactericidal performance against P. acnes.
  • the upper limit of pH is preferably 10 or less, more preferably 9 or less from the viewpoint of skin irritation.
  • the measurement of pH is based on the Japanese Pharmacopoeia 18th Edition, General Test Methods (measurement temperature: 25°C).
  • composition according to the embodiment (I) of the present invention may contain various active ingredients used in pharmaceuticals, quasi-drugs, cosmetics, etc., as necessary, as long as the effects of the invention are not impaired. good.
  • active ingredients used in pharmaceuticals, quasi-drugs, cosmetics, etc., as necessary, as long as the effects of the invention are not impaired. good.
  • anti-inflammatory agents for example, anti-inflammatory agents, antihistamines, antipruritics, wound healing agents, local anesthetics, blood vessel repair agents, keratin softeners, vitamins (excluding component (B)), surfactants (excluding component (C1)), A cooling agent, a moisturizing agent, amino acids, etc.
  • B antioxidants
  • surfactants excluding component (C1)
  • a cooling agent a moisturizing agent, amino acids, etc.
  • Anti-inflammatory agents include, for example, tranexamic acid, glycyrrhetinic acid, glycyrrhizic acid or pharmaceutically acceptable derivatives and salts thereof (e.g., dipotassium glycyrrhizinate), licorice extracts, steroid compounds (hydrocortisone, prednisolone, methylprednisolone , clobetasone, betamethasone, dexamethasone, cortisone, flumethasone, beclomethasone, fluticasone or their pharmaceutically acceptable derivatives and their salts), indomethacin, ibuprofen, ibuprofenpiconol, bufexamac, ufenamate, piroxicam, ketoprofen, salicylic acid or its pharmaceuticals and their salts, dimethylisopropylazulene, angelica extract, radish extract and the like.
  • steroid compounds hydrocortisone
  • antihistamines examples include diphenhydramine, chlorpheniramine, mequitazine, azelastine, emedastine, ketotifen, or pharmaceutically acceptable derivatives and salts thereof.
  • Diphenhydramine hydrochloride and chlorpheniramine maleate are preferred.
  • antipruritic agents include crotamiton, nonylic acid vanillylamide, capsaicin, benzyl nicotinate, capsicum tincture, and the like.
  • wound healing agents include allantoin, zinc oxide, and the like.
  • local anesthetics include lidocaine, lidocaine hydrochloride, dibucaine, dibucaine hydrochloride, and the like.
  • vasoconstrictors include naphazoline, tetrahydrozoline, methylephedrine or salts thereof, and the like.
  • keratin softeners include urea, sulfur, salicylic acid or pharmaceutically acceptable derivatives thereof and salts thereof, nicotinamide, kaolin, bentonite, and the like.
  • Vitamins other than component (B) include vitamin A [retinol and its pharmaceutically acceptable derivatives and salts thereof (e.g., retinol palmitate, retinol acetate, retinol, retinal, retinoic acid, retinoid, etc.).
  • vitamin A retinol and its pharmaceutically acceptable derivatives and salts thereof (e.g., retinol palmitate, retinol acetate, retinol, retinal, retinoic acid, retinoid, etc.).
  • vitamin B6 pyridoxine and its pharmaceutically acceptable derivatives and their salts (e.g., pyridoxine, pyridoxal, etc.)] vitamin C [ascorbic acid and its pharmaceutically acceptable derivatives and their salts (For example, ascorbic acid, sodium ascorbate, magnesium ascorbate phosphate, 3-sodium ascorbyl palmitate phosphate, erythorbic acid, 2-glucoside ascorbate, ascorbyl palmitate, etc.)], vitamin E [tocopherol and its pharmaceutically Acceptable derivatives and salts thereof (e.g.
  • vitamin E acetate tocopherol acetate
  • vitamin E nicotinate vitamin E succinate, vitamin E linolenate, natural vitamin E, etc.
  • vitamin B 1 thiamine and its pharmaceutically acceptable possible derivatives and salts thereof (e.g., thiamine hydrochloride, thiamine nitrate, etc.)]
  • vitamin B2 riboflavin and its pharmaceutically acceptable derivatives and salts thereof (e.g., riboflavin phosphate, riboflavin sodium phosphate, butyric acid riboflavin, flavin adenine dinucleotide sodium, etc.)]
  • vitamin B3 nicot
  • surfactants other than the component (C1) include nonionic surfactants other than the component (C1), ionic surfactants, and the like.
  • Nonionic surfactants include, for example, polyoxyethylene glycerol fatty acid esters such as polyoxyethylene glyceryl monostearate (15); polyoxyethylene tristearate (20) sorbitan (polysorbate 65); Polyoxyethylene sorbitan fatty acid esters such as ethylene (20) sorbitan (polysorbate 85); polyoxyethylene castor oils such as polyoxyethylene (60) castor oil; polyoxyethylene hydrogenated castor oil (10), polyoxyethylene hydrogenated castor oil (60) and other polyoxyethylene hydrogenated castor oils.
  • polyethylene glycol fatty acid esters with HLB of 15.0 or more polyoxyethylene sorbitol fatty acid esters, sorbitan fatty acid esters (polyoxyethylene monooleate (20) sorbitan (polysorbate 80), etc.), polyglycerin fatty acid esters and polyoxyethylene Alkyl ethers may also be mentioned.
  • the ionic surfactant include N-coconut oil fatty acid acyl-DL-alanine triethanolamine liquid.
  • examples of the ionic surfactant include N-coconut oil fatty acid acyl-DL-alanine triethanolamine liquid.
  • the content in the composition for external use is low in order to reduce the influence on the growth of Staphylococcus epidermidis. Specifically, it is preferably less than 3% by mass in the composition, more preferably less than 0.5% by mass, even more preferably 0.01% by mass or less, and particularly preferably not contained (below the detection limit).
  • Cooling agents include, for example, l-menthol, camphor, borneol or analogues thereof, fennel oil, eucalyptus oil, peppermint oil, peppermint oil, spearmint oil and the like.
  • Moisturizers include, for example, polyhydric alcohols (glycerin, 1,3-butylene glycol, 1,2-pentadiol, etc.), sugar alcohols (sorbit, etc.), hyaluronic acid or derivatives thereof, heparin-like substances, polymer compounds ( collagen, chitosan, etc.), amino acids, natural moisturizing factors (sodium lactate, urea, etc.), ceramides, vegetable oils (olive oil, etc.), plant extracts (soybean extract, chamomile extract, aloe extract, etc.).
  • polyhydric alcohols glycerin, 1,3-butylene glycol, 1,2-pentadiol, etc.
  • sugar alcohols sorbit, etc.
  • hyaluronic acid or derivatives thereof heparin-like substances
  • polymer compounds collagen, chitosan, etc.
  • amino acids amino acids
  • natural moisturizing factors sodium lactate, urea, etc.
  • amino acids examples include glutamic acid, aspartic acid, glycine, alanine, serine, aminoethylsulfonic acid (taurine), and pharmaceutically acceptable salts thereof (e.g., ephedrine hydrochloride, methylephenoline hydrochloride, etc.). be done.
  • hydrocarbons such as vaseline, paraffin, liquid paraffin, squalane, ceresin, gelling hydrocarbons and microcrystalline wax; higher fatty acids such as stearic acid, isostearic acid, myristic acid, palmitic acid, oleic acid and behenic acid; cetanol , higher fatty alcohols such as stearyl alcohol and behenyl alcohol; fatty acid ester oils such as isopropyl myristate, octyldodecyl myristate, isopropyl palmitate and diisopropyl adipate; Fatty acid esters; polyhydric alcohols such as propylene glycol and polyethylene glycol; organic solvents such as acetone, methyl ethyl ketone and ethyl acetate; diisopropanolamine, triethanolamine, lauric acid diethanolamide, sodium hydroxide, hydrochloric acid, citric acid, sodium citrate , pH adjusters such as potassium di
  • preservatives such as parabens (methylparaben, ethylparaben, butylparaben), boric acid and borax; cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carmellose, croscarmellose, ethylcellulose and methylcellulose; Modified starch, polyvinyl alcohol, polyvinyl methyl ether, polyvinylpyrrolidone, crospovidone, polyethylene glycol, xanthan gum, carrageenan, sodium alginate, gum arabic, guar gum, tamarint gum, karaya gum, carob gum, tragacanth gum, locust bean gum, pullulan, gelatin , carboxyvinyl polymer, acrylic acid/methacrylate alkyl copolymer, sodium polyacrylate, hydroxyethyl acrylate/acryloyldimethyltaurate crosslinked polymer, quince seed (quince seed
  • composition in the embodiment (I) of the present invention is prepared by mixing the component (A), one or more selected from the components (B) and (C1), and optional components as necessary. Obtainable. Also, from the viewpoint of formulation stability, ethanol may be blended, and in that case, the content is preferably 0.05 to 5% by mass relative to the composition.
  • Embodiment (II) of the present invention is an antibacterial against acne bacteria containing as an active ingredient one or more selected from (B) pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether • It is a fungicide.
  • Embodiment (II) of the present invention will be described in detail below.
  • the (B) component in the embodiment (II) of the present invention is one or more selected from pantothenic acid, calcium pantothenate, sodium pantothenate, panthenol and pantothenyl ethyl ether, and More than one species can be used in combination.
  • Component (B) has an excellent antibacterial/bactericidal effect against P. acnes and does not inhibit the growth of Staphylococcus epidermidis. This is new knowledge of the inventor.
  • panthenol and pantothenyl ethyl ether are preferable as the component (B).
  • Panthenol which is a water-soluble vitamin, is known to have anti-inflammatory action, activation of skin cells, enhancement of skin elasticity and water retention, and the like.
  • Panthenol and salts of pantothenic acid such as calcium pantothenate and sodium pantothenate are converted to pantothenic acid inside the skin and exhibit the above pharmacological effects.
  • Pantothenyl ethyl ether is the ethyl ether of panthenol, which like panthenol is converted to pantothenic acid in the body.
  • the content of component (B) is preferably 0.5% by mass or more in the antibacterial/bactericidal agent because it has more antibacterial/bactericidal effects, and 2% by mass or less because it does not further inhibit the growth of Staphylococcus epidermidis. Preferably, 1 to 2% by mass is more preferable.
  • the content is preferably 0.1 to 2% by mass, more preferably 0.5 to 2% by mass, because antibacterial and bactericidal effects can be obtained at a lower content.
  • Component (C2) in the embodiment (II) of the present invention includes polyethylene glycol fatty acid esters having a fatty acid chain length of 12 to 18, polyoxyethylene sorbit fatty acid esters, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters and polyglycerin. It is one or more selected from fatty acid esters and polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18, and can be used singly or in combination of two or more.
  • the antibacterial/bactericidal effect against P. acnes is further improved, and the antibacterial/bactericidal effect against Staphylococcus aureus is excellent. It can be used as a multiple selective antibacterial/bactericidal agent that is effective and does not inhibit the growth of Staphylococcus epidermidis.
  • the (C2) component has a fatty acid chain length or alkyl chain length of 12 to 18, preferably 12 and 18. By setting it as such fatty acid chain length or alkyl chain length, an antibacterial / bactericidal effect improves.
  • the number of added moles of polyoxyethylene is preferably 6 to 55, more preferably 6 to 40, still more preferably 6 to 25, and particularly preferably 10. By making it more than the said minimum, the antibacterial / bactericidal effect with respect to P. acnes and Staphylococcus aureus improves more. By making it below the above upper limit, the growth of Staphylococcus epidermidis is not further inhibited.
  • the upper limit of HLB of the component (C2) is preferably 18.0 or less, more preferably less than 15.0.
  • the lower limit of HLB of component (C2) is preferably 10.0 or more, more preferably 11.0 or more.
  • the lower and upper limits of the HLB of component (C2) are preferably 10-18, more preferably 11-15. Within the above range, it becomes easier to interact with the cell walls and cell membranes of bacteria, so that excellent antibacterial and bactericidal effects against P. acnes and Staphylococcus aureus are likely to be obtained.
  • HLB Hydrophile Balance
  • polyethylene glycol fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyethylene glycol monooleate (10EO), polyethylene glycol monooleate (6EO), polyethylene glycol monolaurate (10EO), and polyethylene glycol monostearate (10EO). are mentioned. Numerical values in parentheses in the description of the polyethylene glycol fatty acid esters exemplified above represent the average degree of polymerization of ethylene oxide, that is, the average number of repeating oxyethylene groups. The same applies to the following polyoxyethylene sorbitol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene alkyl ethers.
  • polyoxyethylene sorbitol fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyoxyethylene sorbitol monolaurate (6EO), polyoxyethylene sorbitol tetrastearate (60EO), polyoxyethylene sorbitol tetraoleate (60EO), tetra Polyoxyethylene sorbitol oleate (40EO), polyoxyethylene sorbitol tetraoleate (30EO), and the like.
  • the fatty acid chain length is preferably 12-18, more preferably 12.
  • Monoesters are also preferred. Specific examples include sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, sorbitan sesquioleate and the like.
  • polyoxyethylene sorbitan fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan tristearate (polysorbate 65), and monooleic acid. Polyoxyethylene (20) sorbitan (polysorbate 80) and the like.
  • polyglycerol fatty acid esters having a fatty acid chain length of 12 to 18 examples include polyglyceryl-6 monolaurate, decaglyceryl monomyristate, polyglyceryl-10 monostearate, and polyglyceryl-10 monooleate.
  • the numerical value at the end of the notation of the polyglycerin fatty acid ester exemplified above represents the average degree of polymerization of glycerin.
  • polyoxyethylene alkyl ethers having an alkyl chain length of 12 to 18 examples include polyoxyethylene (4) lauryl ether, polyoxyethylene (9) lauromacrogol such as lauryl ether; polyoxyethylene (10) cetyl ether, polyoxyethylene Ethylene (10) oleyl ether and the like can be mentioned.
  • the (C2) component is preferably a polyethylene glycol (4-20 EO) fatty acid ester having a fatty acid chain length of 12-18, preferably a monoester, from the standpoint of sustained moistness (moisturizing feeling).
  • the content of component (C2) is preferably 0.1% by mass or more in the antibacterial/bactericidal agent because it has more antibacterial/bactericidal effects, and is preferably 10% by mass or less because it does not further inhibit the growth of Staphylococcus epidermidis. , more preferably 0.2 to 8% by mass, more preferably 0.7 to 6% by mass.
  • the antibacterial/bactericidal effect against P. acnes and Staphylococcus aureus is further improved, and the intended antibacterial/bacterial effect can be exhibited with a smaller content.
  • the growth of Staphylococcus epidermidis is not further inhibited.
  • the content mass ratio represented by (C2) / (B) is preferably 0.03 to 40, more preferably 1 to 40, further preferably 1 to 15, and 1.3 to 5 is particularly preferred.
  • the antibacterial / bactericidal effect with respect to P. acnes and Staphylococcus aureus improves more.
  • the antibacterial and bactericidal effects against Staphylococcus aureus are further improved.
  • growth of Staphylococcus epidermidis is not inhibited more.
  • (D) component From the viewpoint of not inhibiting the growth of Staphylococcus epidermidis, (D) hydrogen peroxide, sodium hypochlorite, ethanol, isopropanol, ovanol, chloride
  • the content of benzalkonium, benzethonium chloride, cetylpyridinium chloride, cresol, popillon-iodine, iodine, sodium dichloroisocyanurate, chlorhexidine and acrinol, and component (A): isopropylmethylphenol shall be 0.3% by mass or less. is desirable.
  • the component (D) has an excellent antibacterial/bactericidal effect against acne bacteria and does not inhibit the growth of Staphylococcus epidermidis, so the content in the antibacterial/bactericidal agent is less than 0.3% by mass. is more preferable, less than 0.1% by mass is more preferable, less than 0.01% by mass is particularly preferable, and it is most preferably not contained (below the detection limit).
  • an antibacterial/bactericidal agent consisting only of the component (B) and the component (C2) can be used, and optional components of the composition for external use on the skin described later can be It can also be contained within a range that does not impair the effect.
  • the suitable content is also the same as the content of the composition for external use on skin.
  • the antibacterial/bactericidal agent in the embodiment (II) of the present invention is applied to the skin in an appropriate amount (generally 0.1 to 0.5 g, although it depends on the application area), so that at least acne bacteria It is antibacterial and sterilizing, has little effect on Staphylococcus epidermidis, which is a resident skin bacterium, and can be used as a selective antibacterial and sterilizing agent. Furthermore, by using the component (C2) in combination, antibacterial and bactericidal effects against Staphylococcus aureus, which is a harmful Gram-positive bacterium, can be obtained, and it can be used as a multiple selective antibacterial and bactericidal agent.
  • the antibacterial/bactericidal agent of the present invention can be used for selective antibacterial/bactericidal methods against P. acnes, P. acnes, and Staphylococcus aureus.
  • the selective antibacterial and bactericidal effects provide a moisturizing effect and a moisturizing experience.
  • the reason for this is that it does not affect the growth of Staphylococcus epidermidis, which is a resident skin bacterium.
  • Staphylococcus epidermidis breaks down sweat and sebum to produce fatty acids and glycerin.
  • Fatty acids keep the skin slightly acidic and produce antibacterial peptides, which can prevent the growth of Staphylococcus aureus.
  • Glycerin is a moisturizing ingredient that provides moisture to the skin and also plays a role in maintaining the skin barrier function.
  • the antibacterial/bactericidal agent of the embodiment (II) of the present invention is suitable as an acne improving agent, a skin moisturizing agent, and an agent having both effects.
  • the pH of the antibacterial/bactericidal agent in the embodiment (II) of the present invention is preferably 4.5 or higher, more preferably 5.5 or higher, from the viewpoint of antibacterial/bactericidal performance.
  • the upper limit of pH is preferably 10 or less, more preferably 9 or less from the viewpoint of skin irritation.
  • the measurement of pH is based on the Japanese Pharmacopoeia 18th Edition, General Test Methods (measurement temperature: 25°C).
  • the antibacterial/bactericidal composition for external use against acne bacteria containing the antibacterial/bactericidal agent in the embodiment (II) of the present invention is suitable as a selective antibacterial/bactericidal composition for external use on the skin.
  • the amount of the antibacterial/bactericidal agent in the composition for external use on skin is not particularly limited, and is appropriately selected. Suitable contents of components (B), (C2) and (D) in the composition for external use on the skin are the same as the contents of components (B), (C2) and (D) in the above antibacterial/bactericidal agent. are the same.
  • the antibacterial/bactericidal composition for external use against acne bacteria containing an antibacterial/bactericidal agent according to the embodiment (II) of the present invention is suitable as an antibacterial/bactericidal composition for external use on the skin that selectively kills acne bacteria.
  • the amount of the antibacterial/bactericidal agent in the composition for external use on skin is not particularly limited, and is appropriately selected.
  • Preferred contents of components (B) and (C2) in the external composition for skin are the same as the preferred contents of components (B) and (C2) in the antibacterial/bactericidal agent.
  • the content of component (D) can be appropriately set within a range that does not impair the effects of the invention, but from the viewpoint of not inhibiting the growth of Staphylococcus epidermidis, it is preferable It is preferable to make it the same as the content.
  • the formulation and properties of the antibacterial/bactericidal composition for external use on the skin against P. acnes are the same as the formulation and properties of the composition according to the embodiment (I) of the present invention.
  • the external composition for skin of the present invention may contain various active ingredients used in pharmaceuticals, quasi-drugs, cosmetics, etc., if necessary, as long as the effects of the invention are not impaired. Those exemplified in the compositions that are embodiments of (I) can also be included.
  • surfactants other than the component (C2) include those other than the component (C2) among the above components (C1).
  • the external composition for skin according to the embodiment (II) of the present invention can be obtained by mixing the above component (B), optionally component (C2), and optional components with water (the remainder).
  • Example I Comparative Example I
  • a composition for external use was prepared by dissolving the components shown in the table below in purified water.
  • the pH of the resulting composition for external use was measured based on the Japanese Pharmacopoeia 18th Edition/General Test Methods (measurement temperature: 25°C), and the following evaluations were performed. The results are also shown in the table.
  • Antibacterial activity evaluation method Inhibitory concentration (MIC) evaluation Using Staphylococcus epidermidis isolates, which are considered good bacteria, Staphylococcus aureus isolates, which are considered harmful bacteria, and opportunistic bacteria Cutibacterium acnes isolates Then, the antibacterial effect was evaluated by the microdilution method.
  • Bacterial solution preparation A bacterial solution was prepared so that the initial number of bacteria of the following bacteria was 10 7 cells/mL.
  • ⁇ Panthenol Standards of Standards of External Standards, D-pantothenyl alcohol, manufactured by DSM Co., Ltd.
  • Example II Comparative Example II
  • the ingredients shown in the table below were dissolved in purified water to prepare external skin compositions (solutions).
  • the pH of the resulting external composition for skin was measured according to the 18th revision of the Japanese Pharmacopoeia General Test Methods (measurement temperature: 25°C), and the following evaluations were performed.
  • Figures 1 to 3 show dual minimum inhibitory concentration diagrams for the panthenol, polyethylene glycol monolaurate (10EO), and the mixture of panthenol and polyethylene glycol monolaurate (10EO) (1:1.5).
  • (B) panthenol and (C2) polyethylene glycol (10EO) monolaurate (PEG (10EO) monolaurate) alone and the MIC of the mixture of components (B) and (C2)
  • the results were plotted on a graph, the MIC of the (B) component alone and the MIC of the (C2) component alone were connected by a line, and the position of the MIC of the mixture on this line was examined.
  • PEG (10EO polyethylene glycol monolaurate
  • the MIC of the mixture is located inside the line, and it can be seen that the combined use of the (B) component and the (C2) component enhances the antibacterial activity.
  • the MIC of the mixture is located outside the above line. It was confirmed that the growth was not inhibited.
  • Example I and Comparative Example I As in Example I and Comparative Example I above, ⁇ determination criteria for positive growth> were described. In the same manner as in Example I and Comparative Example I, [durability of moist feeling (moisturizing sensation)] was evaluated.
  • a face wash (Table III-1) and a lotion (Table III-2) having the following compositions in embodiments (I) and (II) were prepared by a conventional method (formulation examples 1 to 4). All of them had multiple selective antibacterial and bactericidal actions, and were also excellent in the moist feeling lasting effect.
  • Example II The raw materials used in preparing Example II and Comparative Example II, as well as the Formulation Examples are shown below. Note that descriptions of the same items as in Example I and Comparative Example II are omitted.
  • ⁇ Natural Vitamin E Japanese Standards, Emix-D, manufactured by Tama Biochemical Co., Ltd. ⁇ Phosphate L-ascorbic acid Magnesium: Kangenki, NIKKOL VC-PMG, Nippon Surfactant Kogyo Co., Ltd. Soybean extract: Kangenki, flavosterone SB, Ichimaru Farcos Co., Ltd. Olive oil: Kangenki, NIKKOL olive oil, Nikko Chemicals Co., Ltd. ⁇ Myristic acid: Japanese Standards, LUNAC MY-98, Kao Corporation ⁇ Isostearic acid: Japanese Standards, Isstearic Acid EX, KOKYU ALCOHOL KOGYO Co., Ltd.
  • ⁇ Palmitic acid Japanese Standards, LUNAC P-95 , Kao Co., Ltd.
  • Concentrated glycerin Japanese Standards, Concentrated glycerin for cosmetics, Sakamoto Yakuhin Kogyo Co., Ltd.
  • Sorbit liquid Japanese Standards, Sorbit L-70, Mitsubishi Shoji Food Tech Co., Ltd.
  • Dipropylene Glycol Standards for Chemicals, Dipropylene Glycol DPG-FC, manufactured by Asahi Glass Co., Ltd.
  • N-coconut oil fatty acid acyl-DL-alanine triethanolamine liquid Standards for Standards for Chemicals, Amilite ACT-12, manufactured by Ajinomoto Co., Inc., water Potassium oxide: Kangenki, potassium hydroxide, manufactured by Junsei Chemical Co., Ltd. Lauric acid diethanolamide: Kangenki, Stahome DL, manufactured by NOF Co., Ltd. Polyethylene glycol 1500: Kangenki, PEG-1500, Manufactured by Sanyo Chemical Industries Co., Ltd. Ethylene glycol distearate: Japanese Standards, NIKKOL PEARL-1222, Nippon Surfactant Kogyo Co., Ltd.
  • Disodium edetate Japanese Pharmacopoeia, sodium edetate Chubu Chilest Co., Ltd.
  • Manufactured by paraoxybenzox Methyl acid Regulations of External Harmony, methyl paraoxybenzoate, manufactured by Ueno Pharmaceutical Co., Ltd.
  • Propyl parahydroxybenzoate Regulations of External Harmony, Mekkins P, manufactured by Ueno Pharmaceutical Co., Ltd.
  • Fragrance JP 2002-128658, paragraph [ 0065] to [0071], A to E described in JP-A-2003-73249, or 1 to 4 described in Japanese Patent Application No. 2019-023940 [0016] to [0023] as appropriate To be elected.
  • ⁇ Tocopherol acetate Japanese Pharmacopoeia, manufactured by DSM Co., Ltd.
  • ⁇ 1,3-butylene glycol Standards of Japanese Standards, 1,3-butylene glycol, manufactured by Daicel Chemical Industries, Ltd.
  • ⁇ Trimethylglycine Standards of Standards of Standards, Aminocoat, Asahi Kasei Co., Ltd.
  • Polyoxyethylene hydrogenated castor oil (60EO) External Gen., NIKKOL HCO-60, Nippon Surfactant Kogyo Co., Ltd.
  • Sodium citrate External Gen., trisodium citrate, Showa Kako Co., Ltd.
  • Sodium hyaluronate Sodium hyaluronate, sodium hyaluronate SF20, manufactured by Mitsui Chemicals Fine Co., Ltd.
  • Xanthan gum Specified outside original, Labor Gum (registered trademark) GS-C, DSP Gokyo Food & Chemical Co., Ltd.
  • Hydroxyethyl cellulose Japanese Standards, HEC Daicel EE-820, manufactured by Daicel Finechem Co., Ltd.
  • ⁇ l-menthol Japanese Standards, l-menthol, Takasago Perfumery Co., Ltd.
  • ⁇ Lavender oil Standards of Standards, lavender oil, fragrance Manufactured by Sakae Kogyo Co., Ltd.
  • ⁇ Peppermint oil Standards for External Harmony, Peppermint oil, Manufactured by Koei Kogyo Co., Ltd.
  • ⁇ Eucalyptus oil Standards for Standards for Standards, eucalyptus oil, manufactured by PAYAN BERTRAND

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition externe pour l'acné, la composition contenant (A) du méthylphénol d'isopropyle et un ou plusieurs composants choisis parmi le composant (B) et le composant (C) ci-dessous, et ayant un faible effet sur la croissance de Staphylococcus epidermidis ainsi qu'un excellent effet antimicrobien/stérilisant sur Propionibacterium acnes. (B) : un ou plusieurs éléments choisis parmi l'acide pantothénique, le pantothénate de calcium, le pantothénate de sodium, le panthénol et l'éther de pantothényléthyle. (C) : un ou plusieurs éléments choisis parmi un ester d'acide gras de polyéthylène glycol, un ester d'acide gras de polyoxyéthylène sorbitol, un ester d'acide gras de sorbitane et un ester d'acide gras de polyglycérine ayant un HLB inférieur à 15,0 et une longueur de chaîne d'acide gras de 12 à 18, et un éther alkylique de polyoxyéthylène ayant une longueur de chaîne alkyle de 12 à 18.
PCT/JP2022/047132 2021-12-22 2022-12-21 Composition externe pour l'acné, et composition externe pour effet antimicrobien/stérilisant sélectif d'une bactérie de l'acné WO2023120583A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021-208069 2021-12-22
JP2021208069 2021-12-22
JP2022082393 2022-05-19
JP2022-082393 2022-05-19

Publications (1)

Publication Number Publication Date
WO2023120583A1 true WO2023120583A1 (fr) 2023-06-29

Family

ID=86902556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/047132 WO2023120583A1 (fr) 2021-12-22 2022-12-21 Composition externe pour l'acné, et composition externe pour effet antimicrobien/stérilisant sélectif d'une bactérie de l'acné

Country Status (1)

Country Link
WO (1) WO2023120583A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506367A (ja) * 1992-05-05 1995-07-13 ザ、プロクター、エンド、ギャンブル、カンパニー アクネ治療組成物
JP2002322051A (ja) * 2001-04-24 2002-11-08 Nonogawa Shoji Kk リパーゼ活性阻害剤
JP2011011993A (ja) * 2009-06-30 2011-01-20 Lion Corp ニキビ治療薬
JP2015010059A (ja) * 2013-06-28 2015-01-19 ロート製薬株式会社 医薬組成物
JP2017001993A (ja) * 2015-06-12 2017-01-05 ロート製薬株式会社 アクネ菌バイオフィルム破壊組成物
CN109806194A (zh) * 2017-11-22 2019-05-28 广州慕可生物科技有限公司 一种祛痘凝胶及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506367A (ja) * 1992-05-05 1995-07-13 ザ、プロクター、エンド、ギャンブル、カンパニー アクネ治療組成物
JP2002322051A (ja) * 2001-04-24 2002-11-08 Nonogawa Shoji Kk リパーゼ活性阻害剤
JP2011011993A (ja) * 2009-06-30 2011-01-20 Lion Corp ニキビ治療薬
JP2015010059A (ja) * 2013-06-28 2015-01-19 ロート製薬株式会社 医薬組成物
JP2017001993A (ja) * 2015-06-12 2017-01-05 ロート製薬株式会社 アクネ菌バイオフィルム破壊組成物
CN109806194A (zh) * 2017-11-22 2019-05-28 广州慕可生物科技有限公司 一种祛痘凝胶及其制备方法

Similar Documents

Publication Publication Date Title
RU2537235C2 (ru) Мягко действующие несмываемые композиции для ухода за кожей
TWI417112B (zh) 乳化組成物
US10835572B2 (en) Composition for external application
JP6386911B2 (ja) 外用組成物
WO2015195304A1 (fr) Compositions et procédés pour améliorer l'application topique d'un agent bénéfique comprenant une poudre à des particules liquides et seconde poudre
JP4786630B2 (ja) 皮膚外用剤
JP2014111575A (ja) 外用組成物
JP2016188258A (ja) 抗菌用組成物
JP2005060234A (ja) 皮膚外用剤
JP6906274B2 (ja) 外用組成物、眼科用組成物、抗菌剤、及び抗菌方法
JP2016003208A (ja) 外用組成物
WO2023120583A1 (fr) Composition externe pour l'acné, et composition externe pour effet antimicrobien/stérilisant sélectif d'une bactérie de l'acné
JP2005002087A (ja) 黄色ブドウ球菌の皮膚付着阻害剤
JP7166397B2 (ja) アクネ菌バイオフィルム破壊組成物
JP5951277B2 (ja) アゼライン酸を含有する外用組成物
JP2017001993A (ja) アクネ菌バイオフィルム破壊組成物
JP2005060233A (ja) 皮膚外用剤
JP7361448B2 (ja) トランスグルタミナーゼ発現促進剤
JP2001322990A (ja) 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物
JP2020158493A (ja) パンテノールを含有する油中水型（ｗ／ｏ型）クリーム
JPWO2020004580A1 (ja) 乳酸菌を含有する体臭発生抑制剤
JP5734686B2 (ja) 皮膚外用組成物
JP2017171643A (ja) 外用組成物
JP2023018775A (ja) 外用組成物
JP2023107940A (ja) アクネ菌バイオフィルム破壊組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22911285

Country of ref document: EP

Kind code of ref document: A1